Monthly Archives: November 2018

Biosceptre wins Gold Medal at China’s largest event for promoting innovation and entrepreneurship

Upon invitation from our lead investor Tuspark S&T, Biosceptre recently participated in the Ministry of Education of the People’s Republic of China’s, 4th Annual Internet Plus Innovation and Entrepreneurship Competition. The competition was held by an affiliated institute; the Xiamen University in Fujian, China, in the third week of October 2018.

It has become the country’s largest and most influential platform for promoting innovation and entrepreneurship, and a landmark event in higher education. It fielded 200 local and 60 international entrants, chosen from over 630,000 applicants.

Shaun McNulty, Elle Freeman and Edwin Huang representing Biosceptre at the Xiamen University Competition in October.

A three-person team represented Biosceptre; Edwin Huang and Shaun McNulty attended,   supporting and advising Sydney’s youngest scientist, Elle Freeman.

Elle did a great job  delivering both the initial presentation detailing Biosceptre’s science program, and the follow on defending session. Biosceptre’s efforts were recognised, with an additional opportunity  to present in  a “roadshow” style pitching session to investors.

Elle answers science and business questions from the Competition Panel

Elle’s effort and superb performance was well recognised by the judges, who awarded a gold medal to the Biosceptre team.

The competition award event was hosted at a spectacular location

As well as the great work from Elle, the result was achieved with significant contributions from many of the Biosceptre Team. Julian, Simon, Romain, Daniel, Susan, Brad, and Braden all contributed to the application writing, presentation and review.

Following on from the event Shaun was invited to give an extended lecture of Biosceptres’ science at Tsinghua University in Beijing, which was also well received.

We extend our thanks to Kevin Lin from Tuspark for making these opportunities for Biosceptre possible.

Kevin Lin and Shaun McNulty accept the awards won by Biosceptre

 

 

Update on Phase I trial of Vaccine BIL06v

Biosceptres’ Phase I clinical trial for peptide vaccine BIL06v has now completed enrolment of the first cohort of ten patients at the first dose, and all enrolled patients have received treatment. The trial was initiated in August and, subject to a scheduled safety review this week, it is expected that recruitment of the second cohort will begin before end of November.

Gavin Currie CEO said “It is pleasing that we have been able to exceed forecast recruitment rates through the two sites we have initiated, the Sydney Adventist Hospital Wahroonga, and Sydney Southwest Private Hospital. With a third site ready to initiate if recruitment is an issue going forward, we are confident the trial will continue to progress smoothly. Assuming a similar rate of recruitment for the second cohort the Phase I trial remains on track to be completed around Q3 2019.”